Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT01619332

  • Study
  • In this atlas

Overview

Design
Interventional study; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01619332
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01619332. Quadruple masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
Condition
Type II Diabetes
Intervention (Drug)
Placebo
Intervention (Drug)
Sitagliptin
Intervention (Drug)
LEZ763
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01619332
Content hash
6c1da4f5f2280d300ad985f0063ed27e38d908a68b75d16b986dd4bf3906dd2d